Elena Sena

Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints

E. Glimm, E. Meyer, V. Ratziu, 2022, 2210.06228.

Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and Cons.

F. Tacke, F. Koenig, E. Meyer, 2022, Journal of hepatology.

NAFLD as the metabolic hallmark of obesity

A. Ciudin, J. Pericàs, R. Manzano-Nuñez, 2022, Internal and Emergency Medicine.

Non-Alcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome: A Systematic Review, Meta-Analysis, and Meta-Regression

F. Tacke, J. Pericàs, R. Manzano-Nuñez, 2023, Journal of clinical medicine.

Modifiers of Health-Related Quality of Life by Biological, Psychological and Social Factors

J. Canelo, L. Martín, Elena Sena, 2021 .

Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints

E. Glimm, E. Meyer, F. König, 2022, PloS one.

Uncovering the NAFLD burden in people living with HIV from high‐ and middle‐income nations: a meta‐analysis with a data gap from Subsaharan Africa

J. Lazarus, J. Schattenberg, J. Navarro, 2023, Journal of the International AIDS Society.

Review article: The need for more efficient and patient‐oriented drug development pathways in NASH—setting the scene for platform trials

F. Tacke, Q. Anstee, J. Genescà, 2023, Alimentary Pharmacology and Therapeutics.